Biogen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIIB research report →
Range $175 – $325
Price Chart
About the company
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
- CEO
- Christopher A. Viehbacher
- IPO
- 1991
- Employees
- 7,500
- HQ
- Cambridge, MA, US
AI snapshot
Six angles, distilled from the data.
BIIB is in a strong multi-month uptrend and sits well above its 200-day average, with price near the upper end of its 52-week range. The setup remains constructive after a long recovery from the low-$160s, though the stock is now extended versus its longer-term base.
Street sentiment is constructive, with a Buy consensus and an average target of about $261.83, modestly above the current share price. Recent target resets have trended higher, with multiple firms lifting targets into the $260-$305 range and one upgrade to Outperform, reinforcing positive momentum.
The earnings profile is strong: Biogen has beaten EPS in all 8 of the last 8 quarters, including a 27.2% upside surprise most recently. Next-year EPS estimates are still rising sharply to about $16.26, so shareholders should watch whether management can sustain that step-up in earnings power.
The pattern is mixed but leans to net selling, with one director sale in August standing out against mostly award, vesting, and exempt transactions. Recent activity from officers is largely non-discretionary compensation flow, so the clearest signal is limited rather than aggressively bullish.
Profitability is solid but not elite: gross margin is 75.8% and operating margin is 23.5%, while net margin is 3.38%. Growth is improving on revenue, up 10.6% year over year, and free cash flow remains healthy at $2.36 billion with a 6.30% FCF yield.
Biogen screens as a large-cap biotech with stronger profitability than many peers, supported by high gross margins and a premium earnings profile. The valuation is not cheap, but the market is still pricing it below the consensus target and near the middle of the analyst range.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.89B
- P/E
- 106.85
- Fwd P/E
- 19.96
- PEG
- -1.36
- P/S
- 3.62
- P/B
- 1.97
- EV/EBITDA
- 27.30
- Div Yield
- 0.00%
- Gross Margin
- 70.05%
- Op Margin
- 7.64%
- Net Margin
- 3.37%
- ROE
- 1.86%
- ROIC
- 2.15%
Latest fiscal year · YoY change
- Revenue
- $9.89B+2.2%
- Gross Profit
- $7.49B+1.6%
- Op Income
- $2.47B
- Net Income
- $1.29B-20.8%
- EPS
- $8.83-21.2%
- OCF Growth
- -23.3%
- FCF Growth
- -18.5%
- 52W High
- $261.00
- 52W Low
- $160.36
- 50D MA
- $236.18
- 200D MA
- $206.55
- Beta
- 0.17
- RSI (14)
- 54
- Avg Volume
- 1.09M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biogen posted an 11% revenue increase in Q3, with strong growth from its newer portfolio and Appellis integration helping drive improved 2026 outlook and higher EPS guidance.· October 28, 2026
- Total revenue rose 11% year over year to $2.8 billion, with core pharmaceutical revenue up 18% to $2.0 billion.
- Growth portfolio revenue was about $1.3 billion, up 49% year over year, and now represents about 63% of core pharma revenue.
- SYFOVRE and Empaveli contributed $243 million in Q3, and management said the Appellis deal is now roughly neutral on an operating basis.
- Biogen raised the low end of full-year 2026 non-GAAP diluted EPS guidance to $12.20-$13.00.
- Key pipeline catalysts are near: litifilimab SLE readouts in the first half of December, followed by CLE, AMR, and ZURZUVAE Dravet data next year.
Q3 26 total revenue was $2.8 billion, up 11% year over year. Total third-quarter core pharmaceutical revenue was $2.0 billion, up 18% year over year and 9% quarter over quarter. The growth portfolio generated approximately $1.3 billion, up 49% year over year and 19% quarter over quarter; SYFOVRE and Empaveli together contributed $243 million. Gross margin was not stated on the call. GAAP EPS was a loss of $0.14, impacted by $284 million of acquired IPR&D and milestone expense (about a $1.65 GAAP EPS impact) and about a $1.70 non-GAAP EPS impact. Biogen raised the lower end of its reported full-year 2026 non-GAAP diluted EPS range to $12.20-$13.00. Management also said it expects to repay the remaining $1.4 billion of Appellis-related term loans by the end of 2027, and continues to target at least $250 million of run-rate synergies by the end of 2027.
Christopher Viehbacher framed the quarter as evidence that Biogen’s transformation is working, emphasizing that the company is now growing on top of a stronger commercial base. He said the acquisition of Appellis has integrated better than expected, with synergies being realized faster than planned and operating dilution already “pretty much negligible” aside from financing. He highlighted three priorities: keep scaling the commercial portfolio, deliver a multiyear pipeline readout cycle, and rebuild early development, noting Biogen had gone three years without an IND and now has five INDs this year.
Robin Kramer said Q3 reflected continued commercial momentum, with core pharma revenue of $2.0 billion and total revenue of $2.8 billion, both up year over year. She detailed that the growth portfolio reached about $1.3 billion, SYFOVRE and Empaveli added $243 million, and Q3 free cash flow was $600 million; Biogen ended the quarter with $1.3 billion of cash and $6.4 billion of net debt. She also noted $284 million of acquired IPR&D and milestone expense in Q3, about $50 million of acquired IPR&D expected in Q4, and said the company repaid $400 million of Appellis term loans in the quarter, with $600 million repaid in total so far.
Analysts focused heavily on litifilimab’s SLE readouts, asking about trial design, baseline characteristics, and confidence in the Phase 3 results; management said it had put strategies in place to optimize outcomes, including steroid tapering and background-standard-of-care controls, but would not speculate before the December data. Questions also centered on felzartamab in AMR, where management described strong physician interest, an estimated 11,000-patient market, protocol-driven adoption at transplant centers, and a ramp that would start with a core set of centers and then broaden. Other notable topics were SYFOVRE discontinuation and patient education, SPINRAZA high-dose conversion rates (70% start forms submitted and 50% dosed at quarter-end), LEQEMBI iClick uptake and Part D coverage, and whether PREVAIL for tildacerfont/IgAN should move to a 1-year eGFR endpoint; management said it was already planning to update the endpoint.
Management said Biogen is on track to return to top-line growth next year, supported by a commercial portfolio that is now larger and growing faster than the legacy MS base. The pipeline also has multiple near-term shots on goal across SLE, CLE, AMR, Dravet, and other programs, while early development has been rebuilt with five INDs already this year.
A lot of the investment case still depends on upcoming trial readouts, especially litifilimab in SLE, and management would not add confidence before seeing the data. Several products also face real execution issues: VUMERITY is pressured by Part D formulary tightening, SYFOVRE still has a high early discontinuation problem, LEQEMBI iClick depends on broader reimbursement, and Q4 will face phasing headwinds from Spinraza conversion pull-forward, SKYCLARYS inventory, and lower contract manufacturing revenue.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 147.82M
- Float Shares
- 146.70M
of shares held by institutions
1,106 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BIIB, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Sell | Sep 24, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 18, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Sell | Jun 2, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 5, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | May 11, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | May 11, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | May 12, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 17.45M | ▲ 157.86K |
| Fmr LLC | 16.78M | ▼ 1.44M |
| Blackrock, Inc. | 16.09M | ▲ 103.45K |
| Primecap Management Co | 15.20M | ▲ 42.42K |
| Vanguard Capital Management LLC | 9.67M | ▲ 19.76K |
| State Street Corp | 7.56M | ▲ 217.88K |
| Vanguard Portfolio Management LLC | 6.57M | ▼ 32.77K |
| Geode Capital Management, LLC | 4.51M | ▲ 58.11K |
| Wellington Management Group Llp | 3.12M | ▲ 155.83K |
| Norges Bank | 2.58M | ▲ 2.58M |
| Morgan Stanley | 2.51M | ▲ 95.14K |
| Jpmorgan Chase & Co | 2.04M | ▲ 216.02K |
Held by 2,136 ETFs
Biggest fund positions in BIIB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Grogan Jane | other | 695 |
| Oct 30, 26 | Grogan Jane | other | 345 |
| Oct 30, 26 | Grogan Jane | other | 695 |
| Oct 2, 26 | Godbout Sean | other | 27 |
| Oct 2, 26 | Godbout Sean | other | 8 |
| Oct 1, 26 | Godbout Sean | other | 985 |
| Oct 2, 26 | Godbout Sean | other | 27 |
| Sep 1, 26 | Parini Michael | other | 7,405 |
| Aug 3, 26 | Parini Michael | other | 0 |
| Aug 3, 26 | Minor Lloyd | sell | 593 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIIB coverage
Recent articles, reports, and earnings notes.

Biogen (BIIB): Growth Portfolio Turnaround Gains Traction
Biogen’s growth portfolio now exceeds its legacy MS franchise, driven by SPINRAZA, LEQEMBI, SYFOVRE, and EMPAVELI. The stock looks improved, but execution risk and leverage keep the rating at Hold.

Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.

Biogen (BIIB): Turnaround Gains Traction as Growth Mix Improves
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Want a deeper read on BIIB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Biogen: Why I'm Still Bullish Despite Market Turmoil
seekingalpha.com · Nov 20
Biogen: M&A Growth And Alzheimer's Progress Are Now Priced In (Rating Downgrade)
seekingalpha.com · Nov 19
Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
prnewswire.com · Nov 19
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
defenseworld.net · Nov 19
Biogen Inc. $BIIB Shares Bought by Bogart Wealth LLC
defenseworld.net · Nov 19
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
prnewswire.com · Nov 18
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
marketbeat.com · Nov 17
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
reuters.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice